GlassScriptPhysician profile
Zelalem Yilma
NPI 1164421251
$2,825.09
in general payments reported to CMS, 2019-2025
29 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $311 · 2021: $590 · 2022: $427 · 2023: $691 · 2024: $257 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $315.00 | 2019-2020 | |
| Cardiovascular Systems INC. | $283.52 | 2019-2023 | Diamondback Peripheral |
| Abbott Laboratories | $280.38 | 2020-2025 | Jot Dx |
| Merck Sharp & Dohme LLC | $233.44 | 2023-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $218.13 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $177.67 | 2019-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.66 | 2019-2025 | Lifevest |
| Medtronic, INC. | $144.53 | 2021-2024 | Powercross, Amplatz Goose Neck, Admiral Xtreme |
| Angiodynamics, INC. | $116.09 | 2020-2023 | Venacure 1470 Pro |
| Boston Scientific Corporation | $94.52 | 2019-2025 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $86.03 | 2020-2021 | |
| Novo Nordisk INC | $78.06 | 2022-2023 | Ozempic |
| Cardiva Medical, INC. | $71.00 | 2025 | Optowire |
| Kestra Medical Technology Services, INC. | $69.43 | 2023-2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $63.23 | 2021-2023 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $59.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.22 | 2019-2022 | |
| Pfizer INC. | $42.75 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $40.21 | 2021-2023 | Optimizer |
| Tactile Systems Technology INC | $36.96 | 2019-2020 | |
| Amgen INC. | $33.30 | 2023-2024 | Repatha |
| Terumo Medical Corporation | $23.50 | 2023 | Angio-Seal |
| Heartflow, INC. | $23.31 | 2024 | |
| Abiomed | $22.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.85 | 2019 | |
| Astellas Pharma US INC | $20.86 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.52 | 2021 | |
| Biotronik INC. | $17.00 | 2022 | |
| Cardinal Health 200 LLC | $16.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zelalem Yilma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.